Format

Send to

Choose Destination
Anticancer Res. 2016 Aug;36(8):4233-6.

Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer.

Author information

1
Department of Medical Oncology, University Hospital, Lille, France anne.ploquin@chru-lille.fr.
2
Biomolecular platform, University Hospital, Lille, France.
3
Department of Urodigestive Oncology, Oscar Lambret Center, Lille, France.
4
Department of Oncology, Leonard de Vinci Hospital, Douai, France.
5
Department of Oncology, Joliot Curie Center, Boulogne-sur-mer, France.
6
Department of Medical Oncology, University Hospital, Lille, France Department of Oncology, General Hospital, Boulogne-sur-mer, France.
7
Department of Medical Oncology, University Hospital, Lille, France Department of Oncology, General Hospital, Calais, France.
8
Department of Medical Oncology, University Hospital, Lille, France.

Abstract

BACKGROUND/AIM:

We previously identified three clinical predictive factors of efficacy of cetuximab-irinotecan. Here, we analyzed the clinical characteristics of patients with metastatic colorectal cancer (CRC) in order to detect potent correlations with KRAS mutations.

PATIENTS AND METHODS:

We conducted a retrospective, multicenter study between 2008 and 2012. We included patients with metastatic colorectal adenocarcinomas, previously treated by irinotecan, and with an available KRAS mutation test.

RESULTS:

We included 299 patients. The median age was 60 years; the median number of metastatic sites was 2. One hundred and eight patients (36.1%) had a previous objective response to irinotecan. The median interval between diagnosis and irinotecan discontinuation was 1.94 years. A KRAS mutation was detected in 133 patients (44.5%). In univariate and multivariate analyses, none of the assessed factors was associated with the presence of a KRAS mutation.

CONCLUSION:

No easily clinically assessable parameter was significantly associated with KRAS mutations in patients with colorectal cancer.

KEYWORDS:

Predictive factor; cetuximab; delay of introduction; irinotecan; number of metastatic sites

PMID:
27466537
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center